Yves Renaudineau

Prof. Yves Renaudineau

Immunology, University of Toulouse, Toulouse, Occitanie, France
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2007 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
VDValérie Devauchelle‐Pensec
Valérie Devauchelle‐Pensec
YPYvon Pennec
Yvon Pennec
JMJohanne Morvan
Johanne Morvan
JPJacques‐Olivier Pers
Jacques‐Olivier Pers
CDCapucine Daridon
Capucine Daridon
ASAlain Saraux
Alain Saraux
Objective: There is evidence to support a dominant role for B cells in the pathophysiology of primary Sjögren's syndrome (SS). Therefore, we evaluated the safety and efficacy of anti‐CD20 monoclonal antibody.Methods: Sixteen patients who met the new American‐European Consensus Group criteria for primary SS and scored >50 on at least 2 of 4 visual analog scales (VAS; 100 mm) evaluating global disease, pain, fatigue, and global dryness received infusions of low‐dose rituximab (375 mg/m2) at weeks 0 and 1 without steroid premedication.Results: Slow rituximab infusions (100 mg/hour) were well tolerated, with only 1 patient experiencing serum sickness–like disease. There was a dramatic reduction in B cells of the blood and salivary gland (SG). At week 12, VAS scores with respect to fatigue and dryness (P < 0.05), tender point count (P < 0.035), and quality of life as evaluated by the Short Form 36 questionnaire (SF‐36; P < 0.001) were significantly improved. At week 36, significant improvements were noted in the 4 VAS scores (P < 0.05), tender joint count (P = 0.017), tender point count (P = 0.027), and SF‐36 (P < 0.03). Pulmonary manifestations were ameliorated in 1 patient. Patients with improvements on at least 3 of the 4 VAS scores at any visit (n = 11) had a shorter disease duration than the other patients (n = 5; mean ± SD duration 3.8 ± 5.4 versus 30.1 ± 29.5 years; P = 0.02).Conclusion: Low‐dose rituximab infusions were well tolerated without the benefit of steroids. Infusions induced a rapid depletion of B cells in the blood and SG and could improve primary SS. Controlled studies are needed.

1 May 2010 in Journal of Autoimmunity
Verified
Journal Article
Closed access
WBWesley Brooks
Wesley Brooks
CDChristelle Le Dantec
Christelle Le Dantec
JPJacques-Olivier Pers
Jacques-Olivier Pers
PYPierre Youinou
Pierre Youinou
YRYves Renaudineau
Yves Renaudineau

8 December 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
GBGuillermo Barturen
Guillermo Barturen
SBSepideh Babaei
Sepideh Babaei
FCFrancesc Català-Moll
Francesc Català-Moll
MMManuel Martínez‐Bueno
Manuel Martínez‐Bueno
ZMZuzanna Makowska
Zuzanna Makowska
MAMarta E. Alarcón-Riquelme
Marta E. Alarcón-Riquelme

27 April 2007 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JPJacques‐Olivier Pers
Jacques‐Olivier Pers
VDValérie Devauchelle
Valérie Devauchelle
CDCapucine Daridon
Capucine Daridon
BBBoutahar Bendaoud
Boutahar Bendaoud
RBRozenn Le Berre
Rozenn Le Berre
PYPierre Youinou
Pierre Youinou
Objective: Treatment with rituximab depletes B cells from the peripheral blood (PB) and salivary glands (SGs) of patients with primary Sjögren's syndrome (SS). The purpose of this study was to track the repopulation of B cell subsets in PB as well as their subsequent homing into SGs in patients with primary SS treated with rituximab.Methods: A series of 4‐color flow cytometry experiments delineated B cell subsets in 15 patients with primary SS. All were tested on days 8 and 15 of treatment. Nine of the patients were followed up monthly for 10 months, and the remaining 6 patients were followed up monthly for 24 months. Enzyme‐linked immunosorbent assays were developed to measure serum levels of BAFF and rituximab. SGs were biopsied at the start of the study and 4 months after treatment in 15 patients, 12 months after treatment in 3 patients, and 24 months after treatment in 2 patients.Results: Baseline serum levels of BAFF correlated inversely (r = −0.92, P < 5 × 10−4) with the duration of B cell depletion: the higher the BAFF levels, the shorter the duration of B cell depletion. Four B cell subsets repopulated the PB: plasmablasts (CD19+, CD5−,IgD−,CD38++), transitional type 1 (T1) B cells (CD19+,CD5+,IgD+,CD38++), mature Bm2 cells (CD19+,CD5+/−,IgD+,CD38+/−), and memory B cells (CD19+,CD5−,IgD−,CD38−). Increased numbers of Bm2 cells and decreased memory B cells reappeared with time. Sequential SG biopsies revealed that B cells were absent in these glands for 12 months: they were detected 24 months after rituximab treatment. Memory and T1 B cells were the first B cells identified locally.Conclusion: The timing of B cell repopulation is modulated by BAFF and is followed by reconstitution of the preexisting abnormalities.

1 August 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
VDValérie Devauchelle-Pensec
Valérie Devauchelle-Pensec
JBJean Marie Berthelot
Jean Marie Berthelot
DCDivi Cornec
Divi Cornec
YRYves Renaudineau
Yves Renaudineau
TMThierry Marhadour
Thierry Marhadour
ASAlain Saraux
Alain Saraux
Background Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce adverse events. Objectives To evaluate the efficacy and safety of first-line tocilizumab in PMR. Methods In a prospective open-label study (ClinicalTrials.gov: NCT01713842), 20 glucocorticoid-free patients fulfilling Chuang's PMR criteria, with symptom onset within the last 12 months and a PMR activity score (PMR-AS) >10, each received three tocilizumab infusions at 4-week intervals, without glucocorticoids, followed by oral prednisone from weeks 12 to 24 (0.15 mg/kg if PMR-AS ≤10 and 0.30 mg/kg otherwise). The primary end point was the proportion of patients with PMR-AS≤10 at week 12. Results Baseline median PMR-AS was 36.6 (IQR 30.4–43.8). At week 12, all patients had PMR-AS≤10 and received the low prednisone dosage. Median PMR-AS at weeks 12 and 24 was 4.5 (3.2–6.8) and 0.95 (IQR 0.4–2), respectively (p<0.001 vs baseline for both time points). No patient required rescue treatment. Positron emission tomography-CT showed significant improvements. The most common adverse events were transient neutropenia (n=3) and leucopenia (n=5); in one patient, the second tocilizumab infusion was omitted due to leucopenia. Conclusions Tocilizumab monotherapy is effective in recent-onset PMR. Randomised controlled trials are warranted. Trial registration number NCT01713842.

1 May 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SGSoizic Garaud
Soizic Garaud
CDChristelle Le Dantec
Christelle Le Dantec
SJSandrine Jousse-Joulin
Sandrine Jousse-Joulin
CHCatherine Hanrotel-Saliou
Catherine Hanrotel-Saliou
ASAlain Saraux
Alain Saraux
YRYves Renaudineau
Yves Renaudineau
B lymphocytes from patients with systemic lupus erythematosus (SLE) are characterized by reduced expression levels of membrane CD5. Recent studies from our laboratory have revealed that the level of membrane CD5 is determined by the relative level of two alternative CD5 isoforms; CD5-E1A, which is expressed on the membrane, and CD5-E1B, which is retained in the cytoplasm. Using bisulfite sequencing and methylation-sensitive endonuclease assays we show that the promoter for the alternative CD5-E1B isoform is demethylated in B cells from patients with SLE but not in healthy controls. We go on to show that differential methylation is more pronounced following BCR engagement. As a result of this demethylation, CD5-E1B mRNA is transcribed at the expense of CD5-E1A mRNA transcription. We provide further evidence that production of high IL-6 levels by SLE B cells abrogates the ability of SLE B cells to induce DNA methyl transferase (DNMT1) and then to methylate DNA, an effect that is reversed in the presence of a blocking Ab to the IL-6 receptor. The pattern of demethylation of CpG islands in the CD5-E1B promoter in SLE B cells is similar to those in B cells from healthy controls stimulated in the presence of IL-6, or treated with the methylation inhibitor PD98059. The study reveals that engagement of the BCR with constitutive IL-6 down-regulates the level of membrane CD5, which negatively regulates BCR signaling, in SLE B cells. This altered signaling could, in turn, promote the activation and expansion of autoreactive B cells in SLE patients.